|
CHRAC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62858615482264E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.55986334959834E-13 |
| Normal-vs-Stage2 |
1.79292999999969E-05 |
| Normal-vs-Stage3 |
4.82947015711943E-14 |
| Normal-vs-Stage4 |
3.46733752820683E-12 |
| Stage1-vs-Stage2 |
3.326800E-01 |
| Stage1-vs-Stage3 |
6.232000E-02 |
| Stage1-vs-Stage4 |
4.281800E-02 |
| Stage2-vs-Stage3 |
4.638200E-02 |
| Stage2-vs-Stage4 |
3.280100E-02 |
| Stage3-vs-Stage4 |
5.867200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.55111512312578E-16 |
| Normal-vs-AfricanAmerican |
4.034200E-04 |
| Normal-vs-Asian |
1.05470000510977E-08 |
| Caucasian-vs-AfricanAmerican |
7.731400E-01 |
| Caucasian-vs-Asian |
5.132800E-01 |
| AfricanAmerican-vs-Asian |
9.427200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.17399464886148E-11 |
| Normal-vs-Female |
1.62947433324234E-12 |
| Male-vs-Female |
8.392800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.91568982899071E-12 |
| Normal-vs-Age(41-60Yrs) |
9.04054608952265E-13 |
| Normal-vs-Age(61-80Yrs) |
1.44769751742047E-11 |
| Normal-vs-Age(81-100Yrs) |
4.856700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.393000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.501600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.807400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.778800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.646400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.711400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.706000E-02 |
| Classical-VS-Follicular |
2.305200E-01 |
| Classical-VS-Other |
2.055400E-01 |
| Classical-VS-Normal |
1.66522351463527E-12 |
| Tall-VS-Follicular |
5.135000E-03 |
| Tall-VS-Other |
8.948000E-01 |
| Tall-VS-Normal |
1.36439970432889E-10 |
| Follicular-VS-Other |
1.664990E-01 |
| Follicular-VS-Normal |
1.27370000002625E-06 |
| Other-VS-Normal |
1.183620E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.39339650928605E-11 |
| Normal-vs-N1 |
3.05390157606666E-11 |
| N0-vs-N1 |
2.654200E-01 |
|
|
